Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01HX003028-01 |
| Title: | Effectivenes, Safety, and Patient Preferences of Infliximab Biosimilar Medications for Inflammatory Bowel Disease |
| Principal Investigator: | Jason K. Hou |
| Location: | Houston, TX |
| Congressional District Code: | 9 |
| Research Service: | Health Services R&D |
| Project Period: | February 2020 - January 2024 |
| FY 2021 Funding Amount: | $381,440 |
| Total Award Amount (all years): |
$1,446,515 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Background: Biologic medications (biologics) are highly effective for diseases of the immune system, cancers, and other conditions; however, their high expense is a barrier to care and a burden to the healthcare system. Biologics cannot be exactly copied as “generic” medications. Biosimilars- similar, but not identical versions of biologic medications- are approved with large potential cost savings. However, VA providers and patients have concerns regarding biosimilar switching safety and effect... |